Pre-made Margetuximab benchmark antibody ( Whole mAb, anti-ERBB2/HER2 therapeutic antibody, Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Margetuximab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Margetuximab, sold under the brand name Margenza, is a chimeric IgG monoclonal antibody medication against HER2 used for the treatment of cancer.
| Products Name (INN Index) | Pre-Made Margetuximab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody |
|---|---|
| INN Name | Margetuximab |
| Target | ERBB2 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Raven biotechnologies,GC Pharma,Green Cross,MacroGenics,Merck Sharp & Dohme |
| Conditions Approved | Breast cancer |
| Conditions Active | Gastric cancer,Oesophageal cancer |
| Conditions Discontinued | Bladder cancer,Non-small cell lung cancer,Ovarian cancer,Haematological malignancies,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ERBB2 |
| Package |
